Antibody-drug conjugates (ADCs) have recently been approved to treat HER2-negative metastatic breast cancer (MBC). In an ADC, a cytotoxic chemotherapeutic agent is conjugated to a monoclonal antibody directed against a tumor-associated antigen. Conjugation fundamentally alters tissue…
Upper gastrointestinal (GI) cancers are often undetected until late stages, leading to a poor prognosis. Treatment may be delayed or inappropriately assigned due to a lack of robust biomarker testing. To optimize patient outcomes, oncology clinicians…
Delayed diagnosis of cervical cancer often leads to poor prognosis and lower survival rates, especially in advanced stages. Recent therapeutic advancements, including immune-checkpoint inhibitors and antibody-drug conjugates (ADCs), offer new hope for managing advanced cervical cancer….
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This Community Connections Grand Rounds series will…
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of near- and long-term clinical manifestations makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively…
Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and no therapeutic options which have shown substantial OS benefit. Further,…
As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present…
Despite advancements in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), resistance and recurrence occur frequently and mutations might develop during treatment. Given the diverse range of treatment side effects,…
In the United States, diffuse large B-cell lymphoma (DLBCL) has an incidence rate of 5.5-7.2 per 100,000 individuals, and a death rate of 1.7 per 100,000. Despite its prevalence, integrating the necessary diagnostic and prognostic markers…
Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and…